Editas Medicine (EDIT) Stock Price, News & Analysis

Company Overview

Editas Medicine, Inc. is a clinical-stage biotechnology company developing gene-editing medicines for serious diseases. The company uses CRISPR-based technologies, including CRISPR/Cas12a and CRISPR/Cas9, to make targeted changes to DNA with the goal of treating the underlying causes of disease rather than only managing symptoms.

Editas’ lead program is reni-cel, formerly known as EDIT-301, an investigational ex vivo gene-editing therapy being studied for sickle cell disease and transfusion-dependent beta thalassemia. The company has also pursued in vivo gene-editing programs for inherited retinal disorders and other conditions, although its pipeline may change as clinical and strategic priorities evolve.

Founded in 2013 and headquartered in Cambridge, Massachusetts, Editas conducts research and clinical development primarily in the United States, with clinical studies potentially involving patients and research partners in additional regions. The company is led by President and Chief Executive Officer Gilmore O’Neill. Editas Medicine trades on the Nasdaq under the symbol EDIT.

Key Stats

• Today's Range: $2.68 to $2.83
• 50-Day Range: $2.58 to $3.30
• 52-Week Range: $1.66 to $4.54
• Volume: 17.03 million shs
• Average Volume: 2.98 million shs
• Market Capitalization: $414.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Moderate Buy

Editas Medicine Stock Analysis - MarketRank™

Editas Medicine scored higher than 34% of companies evaluated by MarketBeat, and ranked 707th out of 895 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Editas Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Editas Medicine has a consensus price target of $6.00, representing about 122.2% upside from its current price of $2.70.

Amount of Analyst Coverage

Editas Medicine has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Editas Medicine are expected to decrease in the coming year, from ($0.80) to ($0.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Editas Medicine is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Editas Medicine is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Editas Medicine has a P/B Ratio of 9.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.31% of the float of Editas Medicine has been sold short.

Short Interest Ratio / Days to Cover

Editas Medicine has a short interest ratio ("days to cover") of 8.96.

Change versus previous month

Short interest in Editas Medicine has recently increased by 22.46%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Editas Medicine does not currently pay a dividend.

Dividend Growth

Editas Medicine does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Editas Medicine this week, compared to 4 articles on an average week.

Search Interest

4 people have searched for EDIT on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

6 people have added Editas Medicine to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Editas Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,267.00 in company stock.

Percentage Held by Insiders

3.10% of the stock of Editas Medicine is held by insiders.

Percentage Held by Institutions

71.90% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/21/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:EDIT
• CIK: 1650664
• Web: www.editasmedicine.com
• Phone: (617) 401-9000
• Fax: N/A
• Employees: 87
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Editas Medicine: $6.00
• High Price Target: $8.00
• Low Price Target: $4.00
• Potential Upside/Downside: +122.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$160.06 million
• Net Margins: -157.32%
• Pretax Margin: -157.32%
• Return on Equity: -196.63%
• Return on Assets: -38.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.19
• Quick Ratio: 3.19

Sales & Book Value

• Annual Sales: $40.52 million
• Price / Sales: 10.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.28 per share
• Price / Book: 9.64

Miscellaneous

• Outstanding Shares: 153,580,000
• Free Float: 148,819,000
• Market Cap: $414.67 million
• Optionable: Optionable
• Beta: 2.09